Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nemolizumab (Primary)
  • Indications Prurigo nodularis
  • Focus Registrational; Therapeutic Use
  • Acronyms OLYMPIA 2
  • Sponsors Galderma; Galderma Research & Development

    • Most Recent Events

    • 07 May 2024 According to Galderma media release, The FDA subsequently granted nemolizumab 'Priority Review' for the treatment of prurigo nodularis; its decisions on prurigo nodularis and atopic dermatitis are anticipated in 2024.
    • 07 May 2024 According to Galderma media release, the company has received the FDA and European Medicines Agency (EMA) acceptances for nemolizumab for the treatment of patients with prurigo nodularis and for adolescents and adults with moderate-to-severe atopic dermatitis (AD) in Australia, Singapore, Switzerland, and the United Kingdom. Further submissions to regulatory authorities in additional countries are ongoing.
    • 28 Feb 2024 According to Galderma media release,Results up to 52 weeks from an interim analysis from this trial will be presented at the American Academy of Dermatology (AAD) Annual Meeting from from March 8-12, 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top